
Eris Biotech
Eris Biotech is a YC Winter 2024 (W24) company. Based in Lehi, UT, USA. Team of 2.
About Eris Biotech
Summary
Eris Biotech develops small-molecule drugs that block the pathway cancer cells use to hide from the immune system, allowing the immune system to attack tumors directly. Its lead asset is an orally administered, first-in-class inhibitor that does not target a protein, broadening the eligible patient population beyond what current biologics reach. The therapeutic portfolio focuses on solid tumors, beginning with mesothelioma, and replaces the need for protein-dependent immunotherapy approaches in those indications.
From the Y Combinator listing
Our drugs engage the immune system to fight tumors
We are developing cancer therapeutics using small molecules that inhibit immune suppression. Our drugs engage the immune system to aggressively fight tumors. Our therapeutic portfolio addresses a range of solid tumors, starting with mesothelioma.
Facts
- Healthcare / Healthcare -> Therapeutics
- Lehi, UT, USA
- 2
- Active
- Early
Founders (2)
- Evita Weagel
- Rachel Garlick
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works